A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy

D. Cocito, I. Paolasso, G. Antonini, L. Benedetti, C. Briani, C. Comi, R. Fazio, S. Jann, S. Matà, A. Mazzeo, M. Sabatelli, E. Nobile-Orazio

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69%; this number increased to 81% when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P <0.001). Of the main therapies, PE frequently caused SE (19%), followed by steroids (12.5%) and IVIg (4%). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE.

Original languageEnglish
Pages (from-to)289-294
Number of pages6
JournalEuropean Journal of Neurology
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Plasma Exchange
Steroids
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Italy
Immunoglobulins
Databases
Guidelines

Keywords

  • Chronic inflammatory demyelinating polyneuropathy
  • Corticosteroids
  • Immunoglobulins
  • Immunosuppressant drugs
  • Plasma exchange
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. / Cocito, D.; Paolasso, I.; Antonini, G.; Benedetti, L.; Briani, C.; Comi, C.; Fazio, R.; Jann, S.; Matà, S.; Mazzeo, A.; Sabatelli, M.; Nobile-Orazio, E.

In: European Journal of Neurology, Vol. 17, No. 2, 02.2010, p. 289-294.

Research output: Contribution to journalArticle

Cocito, D. ; Paolasso, I. ; Antonini, G. ; Benedetti, L. ; Briani, C. ; Comi, C. ; Fazio, R. ; Jann, S. ; Matà, S. ; Mazzeo, A. ; Sabatelli, M. ; Nobile-Orazio, E. / A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. In: European Journal of Neurology. 2010 ; Vol. 17, No. 2. pp. 289-294.
@article{bfedfc8c4be4437fb7dfc84e5c1f1170,
title = "A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy",
abstract = "Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69{\%}; this number increased to 81{\%} when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P <0.001). Of the main therapies, PE frequently caused SE (19{\%}), followed by steroids (12.5{\%}) and IVIg (4{\%}). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE.",
keywords = "Chronic inflammatory demyelinating polyneuropathy, Corticosteroids, Immunoglobulins, Immunosuppressant drugs, Plasma exchange, Therapy",
author = "D. Cocito and I. Paolasso and G. Antonini and L. Benedetti and C. Briani and C. Comi and R. Fazio and S. Jann and S. Mat{\`a} and A. Mazzeo and M. Sabatelli and E. Nobile-Orazio",
year = "2010",
month = "2",
doi = "10.1111/j.1468-1331.2009.02802.x",
language = "English",
volume = "17",
pages = "289--294",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy

AU - Cocito, D.

AU - Paolasso, I.

AU - Antonini, G.

AU - Benedetti, L.

AU - Briani, C.

AU - Comi, C.

AU - Fazio, R.

AU - Jann, S.

AU - Matà, S.

AU - Mazzeo, A.

AU - Sabatelli, M.

AU - Nobile-Orazio, E.

PY - 2010/2

Y1 - 2010/2

N2 - Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69%; this number increased to 81% when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P <0.001). Of the main therapies, PE frequently caused SE (19%), followed by steroids (12.5%) and IVIg (4%). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE.

AB - Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69%; this number increased to 81% when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P <0.001). Of the main therapies, PE frequently caused SE (19%), followed by steroids (12.5%) and IVIg (4%). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE.

KW - Chronic inflammatory demyelinating polyneuropathy

KW - Corticosteroids

KW - Immunoglobulins

KW - Immunosuppressant drugs

KW - Plasma exchange

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=74549226510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549226510&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2009.02802.x

DO - 10.1111/j.1468-1331.2009.02802.x

M3 - Article

VL - 17

SP - 289

EP - 294

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 2

ER -